Scarica l'app Stockscreener
10.94
3.80%
0.40
Dopo l'orario di chiusura:
10.94
Neuropace Inc Borsa (NPCE) Ultime notizie
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Increase in Short Interest - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - MarketScreener
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Breakthrough: New Epilepsy Device Shows 82% Seizure Reduction, FDA Study Reveals - Stock Titan
Q1 Earnings Estimate for NeuroPace Issued By Leerink Partnrs - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Sees Large Growth in Short Interest - MarketBeat
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting - The Manila Times
Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes - Stock Titan
NeuroPace Announces Refocusing of Product Portfolio - The Manila Times
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance - MSN
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook By Investing.com - Investing.com Canada
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed - MarketScreener
NeuroPace to terminate distribution relationship for Seeg products - TipRanks
NeuroPace Shifts Focus to Core RNS System - TipRanks
Neuropace Inc Maintaining 2025 Revenue Guidance - MarketScreener
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook - Investing.com
NeuroPace Strategic Pivot: Higher Margins, AI Innovation, and 20% Growth Target Ahead - Stock Titan
NeuroPace (NASDAQ:NPCE) Shares Down 4.3%Should You Sell? - MarketBeat
Where are the Opportunities in (NPCE) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $328,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% – What’s Next? - Defense World
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
NeuroPace Leadership Reveals Growth Strategy: Key Insights Coming at Needham Conference - Stock Titan
(NPCE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Seed Treatment Market Top PlayersNeuropace, Inc., Biotronik, - openPR
Cantor Fitzgerald maintains Overweight on NeuroPace stock By Investing.com - Investing.com Australia
NeuroPace at attractive entry point, remains best idea, says Cantor Fitzgerald - TipRanks
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India
1.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):